Expression of p53 and Bcl-2 proteins in epithelial ovarian carcinoma with different grade of differentiation

Experimental Oncology

Volumn 22, Issue 1-2, 2000, Pages 91-93

  Lukyanova, N Y ^a   Kulik, G I ^a   Yurchenko, O V ^a   Shatrova, K M ^b   Vorobyova, L I ^b   Svintitsky, V S ^b   Evtushenko, G V ^b   Chekhun, V F ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^b Ministry of Health of Ukraine   (Ukraine)

Author keywords

bcl 2; Grade of differentiation; Malignant ovarian carcinoma; Nuclear antigen of proliferating cells; P53

Indexed keywords

EID: 0347937133     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bokhman YaV. Manual on Oncogynecology. Leningrad: Medicine, 1989. 464 pp. (in Russian).
2. Tulyandin ZP. Ovarian cancer: yesterday, today, tomorrow. In: Proc Conf "Modern Tendencies in the Development of Drug Therapy of Tumors", 1997 December 9-10; Moscow, Russia, 1997: 66-9 (in Russian).
3. Betticher D. New targets of anticancer therapy. In: Proc Conf "Modern Tendencies in the Development of Drug Therapy of Tumors", 1997 December 9-10; Moscow, Russia, 1997: 61-7 (in Russian).
4. Vladimirskaya EB, Maschan AA, Rumyancev AG. Apoptosis and its role in development of tumors growth. Hematol Transfusiol 1997; 42: 4-9 (in Russian).
5. Lihtenshtein AV, Shapot VS. Tumor growth: tissues, cells, molecules. Pat Physiol 1997; 3: 35-48 (in Russian).
6. Jaattela M. Escaping cell death: survival proteins in cancer. Exp Cell Res 1999; 248: 30-43.
7. Kastan MB, Onyekwere O, Sidransky D, Volegstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
8. Campos L, Rovulut JP, Sabido O, Oriol P, Roubi N, Vasselon C, Arhimbaud E, Magaud GP, Guiotat D. Hight expression of bcl-2 protein in acute mieloid leukemia cell is associated with poor response to chemotherapy. Blood 1993; 81: 3091-6.
9. Gottesman MM. Report of a meeting: molecular basis of cancer therapy. J Natl Cancer Inst 1994; 86: 1277-85.
10. Eliopoulus AG, Kerr D, Hered J, Hodgkins L, Krajewski S, Reed JC, Yong LS. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 1995; 11: 1217-28.
11. Doll MG, Jasty R, Cooper MG, Thompson GB, Nunez G, Castle P. Bcl-x is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 1995; 55: 2576-82.
12. Berchuk A. Biomarkers in the ovary. J Cell Biochem 1995; 23: 223-6.
13. Pestell KE, Medlow SJ, Titley JS, Kelland LR, Walton MI. Characterisation of the p53 status, Bcl-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines. Int J Cancer 1998; 77: 913-8.
14. Borner MM, Brousset P, Pfanner-Meyer B, Bacchi M, Vonlanthen S, Hotz MA, Altermatt HJ, Schlaifer D, Reed GS, Betticher DS. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer 1999; 79: 952-8.
15. Dipaola RS, Aisner J. Overcoming bcl-2-and p53-mediated resistance in prostate cancer. Semin Oncol 1999; 26: 112-6.
16. Leek RD, Kaklamanis L, Pezella F, Gatter KC, Harris AL. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumors and in situ cancer. Br J Cancer 1994; 69: 135-9.
17. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Fronzo GD, Rilke F, Veronesi U. The bcl-2 protein: a prognostic indicator strongly related to p53 in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994; 86: 499-504.
18. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994; 54: 2095-7.
19. Klemi P-J, Pylkkanen L, Külholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995; 76: 1201-8.
20. Marx D, Binder C, Meden H, Lenthe T, Ziemek T, Hiddemann T, Kuhn W, Schauer A. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer. Anticancer Res 1997; 17: 2233-40.
21. Mano Y, Kikuchi Y, Yamamoto K, Kita T, Hirata J, Tode T, Ishii K, Nagata I. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur J Cancer 1999; 35: 1214-9.
22. L ratios by image cytometric quantitation of immunohistochemical expression in ovarian carcinoma: correlation with prognosis. Cytometry 2000; 42: 61-6.
23. Mikhalap SV. New monoclonal antibody IPO-38 recognizing a nuclear antigen associated with proliferation of normal and malignant cells. [Thesis for degree... cand biol sci]. Kyiv: R.E. Kavetsky Institute of Experimental Pathlogy Oncology and Radiobiology, 1998. 26 pp. (in Russian).